Assigned pulmonary hypertension medication

PreclinicalSmall molecule

Assigned pulmonary hypertension medication is one of 41 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary Arterial HypertensionActive, not recruiting

Pulmonary Arterial HypertensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Reata

Biogen

Phase 3

1 3

Levitra

Bayer

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Atrovent

Inhaled Iloprost

1 9

Actemra

Roche

Phase 2

1 10

Rituxan

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension1 trial

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

Completed· Bayer logo

Bayer··NCT02576002·2,691 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Assigned pulmonary hypertension medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Assigned pulmonary hypertension medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Assigned pulmonary hypertension medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Assigned pulmonary hypertension medication

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Arterial Hypertension1 trial

References

Drug Info

Quick Facts

Related News